📗 Cite This Artifact
TRAF2 Gene
TRAF2 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRAF2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRAF2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TNF Receptor Associated Factor 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>7186</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601985</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000126933</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UAV6</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>E3 ubiquitin ligase (TRAF family)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TRAP, TNF-R2-associated factor, MORT1-associated protein</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Rheumatoid Arthritis, Cancer</td>
</tr>
<tr>
<td class="label">Mediator</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Pro-inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Acute phase response</td>
</tr>
<tr>
<td class="label">Chemokines (CCL2, CXCL8)</td>
<td>Immune cell recruitment</td>
</tr>
<tr>
<td class="label">COX-2</td>
<td>Prostaglandin synthesis</td>
</tr>
<tr>
<td class="l
TRAF2 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRAF2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRAF2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TNF Receptor Associated Factor 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>7186</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601985</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000126933</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UAV6</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>E3 ubiquitin ligase (TRAF family)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TRAP, TNF-R2-associated factor, MORT1-associated protein</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Rheumatoid Arthritis, Cancer</td>
</tr>
<tr>
<td class="label">Mediator</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Pro-inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Acute phase response</td>
</tr>
<tr>
<td class="label">Chemokines (CCL2, CXCL8)</td>
<td>Immune cell recruitment</td>
</tr>
<tr>
<td class="label">COX-2</td>
<td>Prostaglandin synthesis</td>
</tr>
<tr>
<td class="label">iNOS</td>
<td>Nitric oxide production</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TNFR1</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">TNFR2</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">CD40</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">TRAF1</td>
<td>Heterotrimer</td>
</tr>
<tr>
<td class="label">TRAF3</td>
<td>Heterotrimer</td>
</tr>
<tr>
<td class="label">c-IAP1/2</td>
<td>Ubiquitination</td>
</tr>
<tr>
<td class="label">NEMO/IKKγ</td>
<td>Signal transduction</td>
</tr>
<tr>
<td class="label">RIPK1</td>
<td>Kinase binding</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Adaptor binding</td>
</tr>
<tr>
<td class="label">A20</td>
<td>Negative regulation</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>High, increases with activation</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Constitutive, increased in reactive gliosis</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Endothelial cells</td>
<td>Moderate</td>
</tr>
</table>
The TRAF2 gene (TNF Receptor Associated Factor 2) encodes a critical E3 ubiquitin ligase that serves as a central adaptor protein in TNF receptor signaling pathways. Located at chromosome 9q34.3, TRAF2 plays essential roles in regulating NF-κB signaling, apoptosis, cellular stress responses, and inflammatory cascades that are fundamental to both normal immune function and the pathogenesis of neurodegenerative diseases[@arch1998][@bradley2001]. Research has increasingly implicated TRAF2-mediated signaling in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders, making it an important therapeutic target. The protein functions as both an adaptor molecule and an E3 ubiquitin ligase, enabling it to orchestrate complex signaling networks that determine cell survival, death, and inflammatory responses in the brain.
Gene Overview
Protein Structure and Function
Domain Architecture
The TRAF2 protein contains several distinct structural domains that enable its diverse functions:
The overall architecture allows TRAF2 to function as a molecular scaffold, assembling signaling complexes while simultaneously catalyzing ubiquitin chain synthesis.
Enzymatic Activity
TRAF2 exhibits two major enzymatic functions:
E3 Ubiquitin Ligase Activity
TRAF2 synthesizes various types of ubiquitin chains:
- Lys63-linked polyubiquitin chains: Primarily pro-inflammatory signaling, activates NF-κB and MAPK pathways
- Lys48-linked polyubiquitin chains: Target proteins for proteasomal degradation
- Linear polyubiquitin chains: Activate NF-κB in a non-canonical manner
The ubiquitin chains generated by TRAF2 serve as signaling platforms that recruit downstream effectors bearing ubiquitin-binding domains.
Scaffold Function
Beyond its enzymatic activity, TRAF2 serves as a critical adaptor:
- Brings together TNFR signaling components
- Facilitates protein-protein interactions
- Coordinates signal transduction complexes
Role in Neurodegeneration
Alzheimer's Disease
TRAF2-mediated NF-κB signaling is chronically activated in Alzheimer's disease, contributing to disease pathogenesis through multiple mechanisms[@kaltschmidt2005][@chen2012]:
Amyloid-Beta-Induced Inflammation
Amyloid-beta (Aβ) peptides activate NF-κB signaling through TRAF2-dependent pathways:
- Aβ binds to RAGE (Receptor for Advanced Glycation End-products) and activates downstream TRAF2/NF-κB signaling
- Microglial cells show increased TRAF2 expression in response to Aβ
- This creates a feed-forward inflammatory loop that drives chronic neuroinflammation
Neuronal Survival vs Death
The role of TRAF2/NF-κB in neurons is complex:
- Early disease: NF-κB activation can be protective, promoting expression of anti-apoptotic proteins
- Late disease: Chronic NF-κB activation becomes detrimental, promoting inflammatory gene expression
- The balance between canonical and non-canonical NF-κB pathways determines neuronal outcomes
Glial Activation
TRAF2-mediated signaling contributes to reactive gliosis:
- Astrocyte and microglial activation in response to Aβ
- Production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Sustained inflammatory environment that drives disease progression
Tau Pathology
TRAF2 intersects with tau pathology through several mechanisms:
- NF-κB can regulate tau-phosphorylating kinases (GSK3β, CDK5)
- Inflammatory signaling may accelerate tau aggregation
- TRAF2 levels correlate with tau pathology severity in AD brains[@mondragon2019]
Parkinson's Disease
In Parkinson's disease, TRAF2/NF-κB signaling contributes to dopaminergic neuron loss[@ghosh2019][@deleidi2010]:
Dopaminergic Neuron Vulnerability
- Inflammatory signaling exacerbates the inherent vulnerability of dopaminergic neurons in the substantia nigra
- TRAF2-mediated NF-κB activation promotes expression of pro-apoptotic proteins
- Mitochondrial dysfunction and ER stress converge on TRAF2 signaling
Microglial Activation
- Sustained TRAF2/NF-κB activation in microglia within the substantia nigra
- Production of neurotoxic inflammatory mediators
- Chronic activation creates a toxic microenvironment for neurons
Alpha-Synuclein Pathology
TRAF2 interacts with α-synuclein pathology:
- Inflammatory responses may accelerate α-synuclein aggregation
- α-Synuclein can activate NF-κB through TRAF2-dependent pathways
- This creates a pathogenic loop between protein aggregation and inflammation
Amyotrophic Lateral Sclerosis (ALS)
TRAF2 dysregulation has been implicated in ALS[@wu2017]:
- Mutations in ALS-related genes (SOD1, FUS, TARDBP) affect inflammatory signaling
- TRAF2-mediated NF-κB activation in motor neurons
- Glial cell activation and inflammatory-mediated motor neuron death
Neuroinflammation Mechanisms
TRAF2-mediated NF-κB activation drives production of multiple inflammatory mediators[@glass2010]:
Signaling Pathways
Canonical NF-κB Pathway
TRAF2 is essential for canonical (classical) NF-κB signaling:
Non-Canonical NF-κB Pathway
TRAF2 also plays roles in non-canonical NF-κB signaling:
- Regulates NIK (NF-κB-inducing kinase) stability
- Controls processing of p100 to p52
- Affects lymphocyte development and function
MAPK Pathways
TRAF2 coordinates MAPK activation:
- JNK activation through MAP3Ks
- p38 activation in response to stress
- ERK activation for cell survival
Protein Interactions
TRAF2 interacts with numerous proteins to execute its signaling functions:
Expression Pattern
TRAF2 is expressed in various brain cell types with distinct patterns:
Brain expression is influenced by:
- Aging (generally increases)
- Disease state (further upregulated)
- Cytokine exposure (TNF-α, IL-1β)
Clinical Significance
Therapeutic Implications
Targeting TRAF2/NF-κB pathway for neurodegeneration is an active area of research[@oneill2023][@barnes2023]:
Challenges
- NF-κB has both protective and pathogenic roles
- Systemic inhibition increases infection risk
- Timing of intervention critical (early vs. late disease)
Diagnostic Potential
TRAF2 expression may serve as:
- Disease progression marker
- Therapeutic response indicator
- Biomarker for neuroinflammation
Research Methods
Experimental Models
- In vitro: Neuronal and glial cell cultures
- Animal models: Transgenic AD/PD mice
- Human tissue: Post-mortem brain samples
- iPSC models: Patient-derived neurons
Key Techniques
- Immunohistochemistry for localization
- Western blot for protein levels
- qPCR for gene expression
- Luciferase reporter for NF-κB activity
- Ubiquitination assays
Key Publications
See Also
- [NF-κB Signaling Pathway](/mechanisms/nf-kb-signaling-neuroinflammation)
- [TNF-alpha Signaling](/entities/tnf-alpha)
- [Neuroinflammation](/mechanisms/microglia-neuroinflammation)
- [Apoptosis Pathways](/mechanisms/apoptosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [TRAF2 Protein](/proteins/traf2-protein)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Astrocytes](/entities/astrocytes)
External Links
- [NCBI Gene: TRAF2](https://www.ncbi.nlm.nih.gov/gene/7186)
- [UniProt: Q9UAV6](https://www.uniprot.org/uniprot/Q9UAV6)
- [OMIM: 601985](https://www.omim.org/entry/601985)
- [Ensembl: ENSG00000126933](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126933)
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
- [Allen Brain Atlas: TRAF2 expression](https://human.brain-map.org/)
- [Parkinson's Progression Markers Initiative](https://ppmi-info.org/)
References
arch1998, TRAF proteins and modulation of immune receptor signaling (1998) [1](https://doi.org/10.1074/jbc.273.45.29655)
barnes2023, NF-κB pathway in Alzheimer's disease: mechanisms and therapeutic targeting (2023)
bradley2001, TNF receptor-associated factors (TRAFs) (2001) [1](https://doi.org/10.1038/sj.onc.1204784)
chen2012, TRAF2 and TNFR signaling in neurodegeneration (2012)
deleidi2010, Development of neuroinflammation and dopaminergic neuron loss in Parkinson's disease (2010)
ghosh2019, NF-κB in Parkinson's disease: evidence and therapeutic implications (2019)
glass2010, Mechanisms underlying inflammation in neurodegeneration (2010)
hu2019, Role of TRAF2 in neuronal apoptosis and neurological disorders (2019)
kaltschmidt2005, NF-κB in Alzheimer's disease: role in pathogenesis and therapeutic opportunities (2005)
kawai2019, TLR signaling and NF-κB activation (2019)
liu2022, TRAF2 and neuroinflammation in Alzheimer's disease (2022)
matta2019, TRAF2: structure, function, and therapeutic targeting in cancer and neurodegeneration (2019)
mondragon2019, TRAF2 in tau pathology and neurodegenerative diseases (2019)
oneill2023, Targeting the NF-κB pathway for neuroprotection (2023) [1](https://doi.org/10.1038/s41573-023-00723-4)
sun2018, Non-canonical NF-κB signaling pathway in neurodegeneration (2018)
wajant2003, Tumor necrosis factor signaling (2003) [1](https://doi.org/10.1038/sj.cdd.4401235)
wu2017, TNF receptor-associated factor 2 and ALS: genetic and mechanistic studies (2017)
xu2020, TRAF2 in apoptosis and inflammatory diseases (2020)
yan2020, TRAF2 modulates neuroinflammation through NIK-dependent pathways (2020)
zhang2018, TRAF2-mediated NF-κB activation in dopaminergic neurons (2018)
zhao2021, Ubiquitination and neuroprotection: TRAF2 as a therapeutic target (2021)
Pathway Diagram
The following diagram shows the key molecular relationships involving TRAF2 Gene discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-traf2 |
| kg_node_id | TRAF2 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-f5525abb6991 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-traf2'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-traf2?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[TRAF2 Gene](http://scidex.ai/artifact/wiki-genes-traf2)
http://scidex.ai/artifact/wiki-genes-traf2